$CANQF CanaQuest Announces Key Appointments to Tea
Post# of 98044
(Total Views: 126)
Posted On: 06/11/2024 10:46:45 AM
$CANQF CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
https://www.globenewswire.com/news-release/20...rials.html
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®)
TORONTO, ON, June 11, 2024 (GLOBE NEWSWIRE) -- CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare neurological conditions with a primary focus on epilepsy. Furthermore, a nutraceutical version of the formulation, Mentanine™, is scheduled for clinical studies to investigate its potential applications across various indications, paving the way for future clinical trials.
CanaQuest Team Buildout:
Lead Scientific Advisor – Dr. Jordyn Stuart, Ph.D., BS, BS, 12 years of pre-clinical cannabinoid research with emphasis on pharmacology and isolation, purification, and identification of endo- & phyto- cannabinoids; ~6 years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma) Medical Affairs including the launch of Epidiolex®
Chairman of Advisory Board - Dr. Paul Dick, DVM, MSc, Paul Dick & Associates, over 30 years of experience in the pharmaceutical and animal health industries, served on several boards: Animal Health Institute, President of the Ontario Veterinary Medical Association
Dr. Jordyn Stuart, Ph.D., stated, “My extensive experience in cannabinoid research and industry (Greenwich Biosciences, US subsidiary of GW Pharmaceuticals, now part of Jazz Pharmaceuticals) will be leveraged to advance CQ-001 through the clinical pathway to regulatory approval. After examining CanaQuest's portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved CBD-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of CBD alone, while also addressing issues of current formulations through enhanced bioavailability. I am eager to translate these data into clinical practice, with the aim of applying CQ-001 in neurological conditions characterized by a high inflammatory burden.”
Dr. Paul Dick, commented, “Based on my previous product development and commercialization experience and expertise, I believe that the CanaQuest team is well positioned to advance their clinical development program, leading to the timely submission of dossiers and subsequent regulatory review/ approval.”
Preclinical trials were conducted on rodents by Dr. Steven Laviolette, a professor, and neuroscientist, in the field of mental health and cannabinoids, at Western University. These results showed a positive anxiolytic effect and an improvement in the process of forming and storing memories, specifically those related to fear, both of which may be beneficial for conditions such as anxiety, depression, and PTSD.
A pre-clinical MES model of epilepsy conducted on mice at the Ontario Brain Institute revealed that the Drug Candidate CQ-001 demonstrated a 35% increase in potency compared to isolated CBD alone. This indicates that the drug is significantly more effective at reducing seizure activity.
Paul Ramsay, CEO of CanaQuest, stated, "I'm honored to welcome Dr. Stuart and Dr. Dick to our team. Their extensive experience and track record significantly mitigate risks associated with clinical trials and regulatory approvals, streamlining the path to securing drug approvals and enabling the commercialization of cannabidiol-based pharmaceuticals."
Award:
CanaQuest has been awarded, Endocannabinoid Therapeutics Development Company of the Year 2024, in the ninth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, UK.
https://www.globenewswire.com/news-release/20...rials.html
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®)
TORONTO, ON, June 11, 2024 (GLOBE NEWSWIRE) -- CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare neurological conditions with a primary focus on epilepsy. Furthermore, a nutraceutical version of the formulation, Mentanine™, is scheduled for clinical studies to investigate its potential applications across various indications, paving the way for future clinical trials.
CanaQuest Team Buildout:
Lead Scientific Advisor – Dr. Jordyn Stuart, Ph.D., BS, BS, 12 years of pre-clinical cannabinoid research with emphasis on pharmacology and isolation, purification, and identification of endo- & phyto- cannabinoids; ~6 years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma) Medical Affairs including the launch of Epidiolex®
Chairman of Advisory Board - Dr. Paul Dick, DVM, MSc, Paul Dick & Associates, over 30 years of experience in the pharmaceutical and animal health industries, served on several boards: Animal Health Institute, President of the Ontario Veterinary Medical Association
Dr. Jordyn Stuart, Ph.D., stated, “My extensive experience in cannabinoid research and industry (Greenwich Biosciences, US subsidiary of GW Pharmaceuticals, now part of Jazz Pharmaceuticals) will be leveraged to advance CQ-001 through the clinical pathway to regulatory approval. After examining CanaQuest's portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved CBD-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of CBD alone, while also addressing issues of current formulations through enhanced bioavailability. I am eager to translate these data into clinical practice, with the aim of applying CQ-001 in neurological conditions characterized by a high inflammatory burden.”
Dr. Paul Dick, commented, “Based on my previous product development and commercialization experience and expertise, I believe that the CanaQuest team is well positioned to advance their clinical development program, leading to the timely submission of dossiers and subsequent regulatory review/ approval.”
Preclinical trials were conducted on rodents by Dr. Steven Laviolette, a professor, and neuroscientist, in the field of mental health and cannabinoids, at Western University. These results showed a positive anxiolytic effect and an improvement in the process of forming and storing memories, specifically those related to fear, both of which may be beneficial for conditions such as anxiety, depression, and PTSD.
A pre-clinical MES model of epilepsy conducted on mice at the Ontario Brain Institute revealed that the Drug Candidate CQ-001 demonstrated a 35% increase in potency compared to isolated CBD alone. This indicates that the drug is significantly more effective at reducing seizure activity.
Paul Ramsay, CEO of CanaQuest, stated, "I'm honored to welcome Dr. Stuart and Dr. Dick to our team. Their extensive experience and track record significantly mitigate risks associated with clinical trials and regulatory approvals, streamlining the path to securing drug approvals and enabling the commercialization of cannabidiol-based pharmaceuticals."
Award:
CanaQuest has been awarded, Endocannabinoid Therapeutics Development Company of the Year 2024, in the ninth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, UK.
(0)
(0)Scroll down for more posts ▼